8th Jun 2016 11:11
LONDON (Alliance News) - GlaxoSmithKline PLC on Wednesday said its sirukumab treatment for rheumatoid arthritis has met both primary endpoints in its phase three study.
The results are being presented by Glaxo at the Annual European Congress of Rheumatology and follow on from positive top-line results from the trials announced in December.
Inhibition of joint destruction was significantly higher for patients treated with sirukumab, Glaxo said, while the drug also delivered an at least-20% improvement in rheumatoid arthritis symptoms, as measured by the American College of Rheumatology response criteria.
"Many patients with rheumatoid arthritis continue to suffer with this debilitating and painful disease despite the availability of several treatment options. This study showed that sirukumab inhibited the progression of joint damage and improved the signs and symptoms of disease, disability and quality of life measures," said Paul-Peter Tak, chief immunology officer at Glaxo.
Glaxo shares were down 0.7% to 1,452.5 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline